A multi-center, open-label phase 1/1b dose finding, safety, and pharmacokinetic study of MBRC-101, an Anth-EphA5 monomethyl auristatin (MMAE) antibody drug conjugate, in advanced refractory solid tumors.

被引：0

作者：

Sen, Shiraj

Salkeni, Mohamad Adham

Albany, Costantine

Gandhi, Neel Jitendra

Edenfield, William Jeffery

Parsons, Kellogg

Chen, Isan

Powderly, John D., II

机构：

[1] NEXT Oncol, Dallas, TX USA

[2] NEXT Oncol, Fairfax, VA USA

[3] Horizon Oncol & Res Ctr, Lafayette, IN USA

[4] Carolina BioOncol Inst, Huntersville, NC USA

[5] Prisma Hlth Canc Inst, Greenville, SC USA

[6] MBrace Therapeut, San Diego, CA USA

[7] MBrace Therapeut Inc, La Jolla, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS3161

引用

页数：1